<DOC>
	<DOCNO>NCT01453088</DOCNO>
	<brief_summary>In study investigator compare standard regimen newly establish regimen melphalan bortezomib .</brief_summary>
	<brief_title>Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib Pts With Multiple Myeloma Age 65 Years Older</brief_title>
	<detailed_description>In study investigator compare standard regimen newly establish regimen melphalan bortezomib . Conditioning Regimens : Treatment arm A Melphalan administer dose 200mg/m2 rapid intravenous infusion via central peripheral vein 30 minute one hour . Melphalan give single dose ( split 2 day ) give day-1 . Dosing base body surface area calculate use actual body weight Stem cell infusion : Stem cell infusion occur day 0 least 20 hour infusion melphalan . The infusion peripheral blood stem cell do accordance Blood Marrow Transplant program standard operating procedure . Filgrastim administer dose 5 mcg/kg ( rounded vial size ) every day start day+3 daily start day 9 engraftment ( least ) . Treatment arm B Bortezomib : Bortezomib administer rapid I.V . push ( 3-5 second ) via central peripheral vein flow saline line . Bortezomib administer time day -4 least 20 hrs start melphalan infusion day -1 . Dosing base actual body weight . Dexamethasone administer dose 20 mg IV prior bortezomib infusion . Melphalan : Melphalan administer dose 200mg/m2 rapid intravenous infusion via central peripheral vein 30 minute one hour . Melphalan give single dose ( split 2 day ) give day-2 . Dosing base body surface area calculate use actual body weight Stem cell infusion : Stem cell infusion occur day 0 least 18 hour infusion bortezomib . The infusion peripheral blood stem cell do accordance Blood Marrow Transplant program standard operating procedure . Filgrastim administer dose 5 mcg/kg ( rounded vial size ) every day start day+3 daily start day 9 engraftment ( least ) . Post-transplant Supportive Care administer accordance Blood Marrow Transplant program standard operating procedure .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Confirmed diagnosis multiple myeloma le 12 month since initiation systemic therapy Age â‰¥60 year time transplantation KPS 70100 % Recovery complication prior therapy Diagnosis multiple myeloma Chemotherapy radiotherapy within 8 day initiate treatment study Prior doseintense therapy within 56 day initiate treatment study Uncontrolled bacterial , viral , fungal parasitic infection Uncontrolled CNS metastasis Known amyloid deposition heart Organ dysfunction LVEF &lt; 40 % cardiac failure responsive therapy FVC , FEV1 DLCO &lt; 40 % predict and/or receive supplementary continuous oxygen Evidence hepatic synthetic dysfunction total bilirubin &gt; 2x AST &gt; 3x ULN Measured creatinine &lt; 20ml/min Sensory peripheral neuropathy grade 4 within 14 day enrollment Karnofsky score &lt; 70 % Life expectancy limit comorbid illness</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>multiple myeloma</keyword>
	<keyword>transplant</keyword>
</DOC>